These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28789453)

  • 21. Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer.
    Kato A; Naitoh I; Naiki-Ito A; Hayashi K; Okumura F; Fujita Y; Sano H; Nishi Y; Miyabe K; Inoue T; Hirano A; Takada H; Yoshida M; Hori Y; Natsume M; Kato H; Takahashi S; Kataoka H
    Pancreas; 2022 Apr; 51(4):372-379. PubMed ID: 35695793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine.
    Yu J; Gao J; Lu Z; Li Y; Shen L
    Med Oncol; 2012 Dec; 29(5):3029-34. PubMed ID: 22766748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
    Dingemans AM; Witlox MA; Stallaert RA; van der Valk P; Postmus PE; Giaccone G
    Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.
    Miyata Y; Matsuo T; Nakamura Y; Yasuda T; Ohba K; Takehara K; Sakai H
    Anticancer Res; 2018 Mar; 38(3):1629-1635. PubMed ID: 29491095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway.
    Levallet G; Bergot E; Antoine M; Creveuil C; Santos AO; Beau-Faller M; de Fraipont F; Brambilla E; Levallet J; Morin F; Westeel V; Wislez M; Quoix E; Debieuvre D; Dubois F; Rouquette I; Pujol JL; Moro-Sibilot D; Camonis J; Zalcman G;
    Mol Cancer Ther; 2012 May; 11(5):1203-13. PubMed ID: 22411898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased expression of class III β-tubulin is associated with unfavourable prognosis in patients with malignant melanoma.
    Shimizu A; Kaira K; Yasuda M; Asao T; Ishikawa O
    Melanoma Res; 2016 Feb; 26(1):29-34. PubMed ID: 26426765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of TUBB3, TS and ERCC1 mRNA expression on chemoresponse and clinical outcome of advanced gastric cancer by multiplex branched-DNA liquid chip technology].
    Huang J; Hu H; Xie Y; Tang Y; Liu W; Zhong M
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jun; 38(6):582-9. PubMed ID: 23828702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of microtubule associated protein-tau and β-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer.
    Yu J; Gao J; Lu Z; Gong J; Li Y; Dong B; Li Z; Zhang X; Shen L
    Eur J Cancer; 2014 Sep; 50(13):2328-35. PubMed ID: 25016949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High expression of class III β-tubulin in small cell lung carcinoma.
    Powell S; Kaizer A; Koopmeiners JS; Iwamoto C; Klein M
    Oncol Lett; 2014 Feb; 7(2):405-410. PubMed ID: 24396456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of excision repair cross-complementation group 1, breast cancer susceptibility 1, and β III-tubulin in thymic epithelial tumors.
    Kaira K; Serizawa M; Koh Y; Miura S; Kaira R; Abe M; Nakagawa K; Ohde Y; Okumura T; Naito T; Murakami H; Takahashi T; Kondo H; Nakajima T; Endo M; Yamamoto N
    J Thorac Oncol; 2011 Mar; 6(3):606-13. PubMed ID: 21289518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S.
    Di Bartolomeo M; Raimondi A; Cecchi F; Catenacci DVT; Schwartz S; Sellappan S; Tian Y; Miceli R; Pellegrinelli A; Giommoni E; Aitini E; Spada F; Rosati G; Marchet A; Pucci F; Zaniboni A; Tamberi S; Pressiani T; Sanna G; Cantore M; Mosconi S; Bolzoni P; Pinto C; Landi L; Soto Parra HJ; Cavanna L; Corallo S; Martinetti A; Hembrough TA; Pietrantonio F
    Tumori; 2021 Apr; 107(2):150-159. PubMed ID: 32522106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive and Prognostic Value of TUBB3, RRM1, APE1, and Survivin Expression in Chemotherapy-Receiving Patients with Advanced Non‑Small Cell Lung Cancer.
    Raungrut P; Tanyapattrapong S; Jirapongsak J; Geater SL; Thongsuksai P
    Asian Pac J Cancer Prev; 2023 Sep; 24(9):3003-3013. PubMed ID: 37774051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
    Toffart AC; Timsit JF; Couraud S; Merle P; Moro-Sibilot D; Perol M; Mastroianni B; Souquet PJ; Girard N; Jeannin G; Romand P; Chatellain P; Vesin A; Brambilla C; Brambilla E
    Lung Cancer; 2014 Feb; 83(2):182-8. PubMed ID: 24388706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal adenocarcinoma.
    Kato A; Naiki-Ito A; Naitoh I; Hayashi K; Nakazawa T; Shimizu S; Nishi Y; Okumura F; Inoue T; Takada H; Kondo H; Yoshida M; Takahashi S; Joh T
    Hum Pathol; 2018 Apr; 74():92-98. PubMed ID: 29339176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome.
    Schrader C; Meusers P; Brittinger G; Teymoortash A; Siebmann JU; Janssen D; Parwaresch R; Tiemann M
    Leukemia; 2004 Jul; 18(7):1200-6. PubMed ID: 15116121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High levels of class III β-tubulin expression are associated with aggressive tumor features in breast cancer.
    Lebok P; Öztürk M; Heilenkötter U; Jaenicke F; Müller V; Paluchowski P; Geist S; Wilke C; Burandt E; Lebeau A; Wilczak W; Krech T; Simon R; Sauter G; Quaas A
    Oncol Lett; 2016 Mar; 11(3):1987-1994. PubMed ID: 26998111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multidrug resistance-associated biomarkers PGP, GST-pi, Topo-II and LRP as prognostic factors in primary ovarian carcinoma.
    Lu D; Shi HC; Wang ZX; Gu XW; Zeng YJ
    Br J Biomed Sci; 2011; 68(2):69-74. PubMed ID: 21706917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients.
    Jakobsen JN; Santoni-Rugiu E; Sørensen JB
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):43-51. PubMed ID: 24220933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
    Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
    Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of Class III Beta-Tubulin Is Associated with Invasive Potential and Poor Prognosis in Thyroid Carcinoma.
    Na HY; Park M; Kim YA; Won JK; Park YJ; Shin SA; Lee S; Oh S; Kim JE
    J Clin Med; 2020 Nov; 9(12):. PubMed ID: 33256003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.